PHK
WHWK

Point72 Hong Kong’s Whitehawk Therapeutics WHWK Stock Holding History

Point72 Hong Kong’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,067
Closed -$15K – 1762
2022
Q3 		$15K Buy
1,067
+289
+37% +$3.8K ﹤0.01% 1672
2022
Q2 		$10K Buy
+778
New +$11.6K ﹤0.01% 1675

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Point72 Hong Kong's WHWK Position: Q4 2022 in Review

Point72 Hong Kong sold out of Whitehawk Therapeutics (WHWK) in Q4 2022, closing a stake of 1,067 shares — an estimated $15K sold.

Point72 Hong Kong first reported a position in WHWK in Q2 2022 and held it in 2 quarters. The position peaked at $15K in Q3 2022. 76 funds tracked by Wall St. Rank hold WHWK as of Q4 2022.

  • Point72 Hong Kong reported no remaining Whitehawk Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 1,067 Whitehawk Therapeutics shares in Q4 2022, an estimated $15K.
  • Point72 Hong Kong first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 2 quarters.
  • Point72 Hong Kong's Whitehawk Therapeutics position peaked at $15K in Q3 2022.
  • 76 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.